Abstract Body

Background

Substance use disorders (SUD) adversely affect the prognosis of people with HIV (PWH) by impairing immune responses, reducing adherence to antiretroviral therapy (ART), and increasing the burden of comorbidities. Our previous findings showed that methamphetamine (MA) exposure in PWH under ART was associated with activation of the inflammasome cascade in both innate and adaptive immune cells, as well as increased HIV transcription, which could be upstream of their worse prognosis.

Methods

To validate the direct effect of MA on the modulation of the inflammasome pathway, we conducted a randomized, placebo-controlled crossover trial (NCT03825536), investigating the effects of low-dose oral MA in ART-suppressed PWH without history of MA use disorder. Participants (n=10) received a total of the FDA-approved pediatric daily dose of oral MA (given as two doses, 10 mg + 15 mg) vs. placebo. Blood samples were collected at baseline, 0.5, 2, 2.5, 4, 24 hours, and 31 days post-intervention. Serum MA levels, plasma cytokine concentrations, and cellular HIV Pol transcript quantifications were performed. Immunophenotyping of peripheral blood mononuclear cells (PBMCs) was performed by flow cytometry ex vivo and following stimulation with LPS. 

Results

MA was detected in the serum of all participants 30 minutes after the first dose and continued to increase, reaching a peak at 4 hours post-intervention (74.6 ng/ml ±9.74), followed by a decline at 24 hours (26 ng/ml ±7.82). No MA was detected in the serum during placebo administration. Independently of the arm of the study, several participants had detectable HIV Pol RNA transcripts.

Paired analysis revealed increased frequencies of inflammatory monocytes (CD14⁻CD16⁺) and of proinflammatory cytokines IL-1β and IL-18, 4 hours post-intervention, concomitant with decreases in FLT3LG and IL-15 (FDR-adjusted p-value < 0.1). While the cytokine levels returned to baseline after 24 hours, the stimulation of PBMCs in vitro with lipopolysaccharide (LPS) led to increased IL-1β expression in different immune subsets after MA administration, which persisted up to 31 days post-intervention, indicating a sustained modulation of immune function. These immune signatures recapitulate those previously observed in PWH-ART with MA-SUD.

Conclusions

Our results validate MA as the upstream inducer of inflammasome activation, reshaping immunity. These findings suggest that targeting this pathway may offer a potential strategy to restore homeostasis in PWH-ART with MA-SUD.